Abstract:Nisin is an antimicrobial polypeptide produced by Lactococcus lactis and is believed nontoxic to humans. The objective of this study was to evaluate a nisin-based formulation for the treatment of bovine clinical mastitis in lactating dairy cattle. A total of 92 cows with 107 clinically mastitic quarters were randomly assigned to nisin- (48 cows with 51 quarters) and gentamicin (GM)-treated (44 cows with 56 quarters) groups. In the nisin-treated group, cows received an intramammary infusion of nisin at a dose of 2,500,000 IU; in the GM-treated group, intramammary infusion of GM was administered at a dose of 0.8 g. Results indicated that nisin offered a clinical cure rate similar to GM (90.2 vs. 91.1%) and no difference in bacteriological cure rate than GM-treated group (60.8 vs. 44.6%, respectively). Proportion of the quarters with milk somatic cell counts <500,000 cells/mL was not different in the nisin-treated group (50.0 and 47.8%) compared with the GM-treated group (33.3 and 37.3%) 1 and 2 wk after treatment. Of 17 Staphylococcus aureus isolates, 82.5% were resistant to penicillin, and 35.3% to GM, but none of them to nisin. Nisin therapy eliminated 54.5% (6 of 11) of S. aureus IMI, whereas GM eliminated 33.3% (2 of 6). Nisin in milk (4.5 +/- 0.8 IU/mL) was detected only at 12 h following intramammary infusion, which was much lower than the upper limit (500 mg/mL) allowed as preservative in milk by the China authority. Because of its efficacy in the treatment of bovine clinical mastitis, especially resistant Staph. aureus-caused IMI, as well as its safety in humans, nisin deserves further study to clarify its effects on mastitis caused by different mastitis pathogens on a larger scale.

Effect of Self-developed Vaccine Injection on the Prevention and Treatment of Recessive Mastitis in Cow

Effect of Teat Dipping and Dry Cow Therapy on Mastitis in a Commercial Dairy Herd in China

Development and Immune Effect Evaluation of Inactivated Vaccine Against Mastitis in Dairy Goats

Therapeutic Effect of Nisin Z on Subclinical Mastitis in Lactating Cows.

Changes of main constituents in milk from cows with subclinical mastitis caused by Streptococcus agalactiae after intramammary infused with Nisin

The immunity effectiveness comparisons of houhai point inoculation and conventional inoculation of the triple inactived vaccine of dairy cattle mastitis

Injection of thymopentin in the super mammary lymph node for treatment of subclinical mastitis in dairy cows

Development and Immune Efficacy of Polyvalent Staphylococcus Aureus Vaccine Against Bovine Mastitis

Evaluation of the efficacy of a new inactivated vaccine against Staphylococcus aureus, Echerchia coli and Mycoplasma bovis mastitis in cows

Effects of a Chinese Traditional Medicine on the Cell Immune Function of Recessive Mastitis Cows

Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows.

Progress on Subclinic Mastitis in Dairy Cows

Effect of Subcutaneous Injection of Ginseng on Cows with Subclinical Staphylococcus Aureus Mastitis.

Research Progress on the Vaccine of Dairy Mastitis for Prevention and Cure

Development and Efficacy Evaluation of an SP01-adjuvanted Inactivated Escherichia Coli Mutant Vaccine Against Bovine Coliform Mastitis

nhibition to pathogens of cow recessive mastitisby Chinese herb compound prescription in vitro

Curative Effects of Compound Immunocompetence Active Factors on Subclinical Mastitis of Dairy Cows

Investigation on Prevalent Bovine Mastitis-Causing Bacteria in Ningbo and Comprehensive Control Trial

Changes of Daily Milk Production and Major Constituents of Milk after Intramammary Infused with Nisin of Bovine Clinical Mastitis.

Effect Evaluation about Pathogenic Bacteria of Diary Cow Mastitis Treated with Ruyuankang

Efficacy of Vaccination and Nisin Z Treatments to Eliminate Intramammary Staphylococcus Aureus Infection in Lactating Cows.